<p>Bio-Techne Corp (NASDAQ:TECH - 獲取免費報告) 的股價在週三下跌了 10.8%，原因是其財報表現低於預期。該公司股價最低曾達到 49.77 美元，最後交易價為 50.5320 美元。在交易過程中，約有 2,041,218 股成交，較日均成交量 2,317,194 股下降了 12%。該股票此前收盤價為 56.68 美元。</p>
<ul>
<li>Bio-Techne、J2 Global 和 InMode 從底部突破，接近買入點</li>
</ul>
<p>這家生物技術公司報告本季度每股收益為 0.53 美元，低於市場共識預期的 0.55 美元，差距為 0.02 美元。該公司本季度的收入為 3.1142 億美元，而分析師預期為 3.1608 億美元。Bio-Techne 的淨利潤率為 6.67%，股本回報率為 13.94%。該公司的收入同比下降了 1.5%。在去年同期，該公司每股收益為 0.56 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>TECH 已成為多份研究分析報告的主題。Benchmark 在 2 月 3 日的研究報告中重申了對 Bio-Techne 股票的 “買入” 評級。富國銀行在 2 月 6 日的研究報告中將 Bio-Techne 的目標價從 70.00 美元上調至 76.00 美元，並給予該股票 “超配” 評級。Zacks Research 在 2 月 9 日的報告中將 Bio-Techne 的評級從 “強烈賣出” 上調至 “持有”。Evercore 在 2 月 5 日的報告中將 Bio-Techne 的目標價從 62.00 美元上調至 68.00 美元，並給予該公司 “持平” 評級。最後，TD Cowen 在 3 月 17 日的報告中重申了對 Bio-Techne 股票的 “買入” 評級。一位投資分析師給予該股票 “強烈買入” 評級，九位給予 “買入” 評級，三位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Bio-Techne 目前的平均評級為 “適度買入”，共識目標價為 72.77 美元。</p>
<p><strong>閲讀我們對 Bio-Techne 的最新分析</strong></p>
<h2>Bio-Techne 的機構交易</h2>
<p>幾家對沖基金最近調整了對該股票的持有。Asset Management One Co. Ltd.在第四季度將其在 Bio-Techne 的持股增加了 2.7%。Asset Management One Co. Ltd.目前擁有 5,752 股該生物技術公司的股票，價值 341,000 美元，此前在上個季度增持了 153 股。Accredited Investors Inc.在第四季度將其在 Bio-Techne 的持股增加了 2.7%。Accredited Investors Inc.目前擁有 6,052 股該生物技術公司的股票，價值 356,000 美元，此前增持了 161 股。Allworth Financial LP 在第三季度將其在 Bio-Techne 的持股增加了 28.4%。Allworth Financial LP 目前擁有 786 股該生物技術公司的股票，價值 44,000 美元，此前增持了 174 股。Oppenheimer &amp; Co. Inc.在第四季度將其在 Bio-Techne 的持股增加了 3.5%。Oppenheimer &amp; Co. Inc.目前擁有 5,351 股該生物技術公司的股票，價值 315,000 美元，此前增持了 181 股。最後，Angeles Wealth Management LLC 在第三季度將其在 Bio-Techne 的持股增加了 3.4%。Angeles Wealth Management LLC 目前擁有 5,703 股該生物技術公司的股票，價值 317,000 美元，此前增持了 189 股。98.95% 的股票由機構投資者持有。</p>
<h2>Bio-Techne 股價下跌 10.6%</h2>
<p>該公司的市值為 79.2 億美元，市盈率為 99.38，市盈增長比率為 3.60，貝塔值為 1.41。該公司的債務與股本比率為 0.13，速動比率為 3.08，流動比率為 4.54。該公司的 50 日移動平均線為 54.70 美元，200 日移動平均線為 59.71 美元。</p>
<h2>Bio-Techne 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Bio-Techne Corporation NASDAQ: TECH 是一家全球生命科學公司，開發、製造和銷售高質量的試劑、儀器和服務，服務於研究、診斷和生物加工市場。其核心產品包括重組蛋白、抗體、免疫測定、核酸探針和試劑盒、單細胞分析解決方案以及自動化蛋白分析系統。旗艦品牌如 R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 為研究人員和臨牀醫生提供可靠的細胞生物學、免疫學、蛋白質組學和基因組學應用工具。</p>
<p>Bio-Techne 總部位於明尼阿波利斯，明尼蘇達州，通過直接銷售、分銷商和戰略合作伙伴關係為北美、歐洲和亞太地區的客户提供服務。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Bio-Techne</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Bio-Techne 嗎？</h2>
<p>在你考慮 Bio-Techne 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Bio-Techne 並不在名單上。</p>
<p>雖然 Bio-Techne 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TECH

<p>Bio-Techne Corp（納斯達克代碼：TECH）股價下跌 10.8%，至 50.53 美元，此前公司公佈的財報令人失望，每股收益（EPS）低於預期 0.02 美元，營收低於預期 466 萬美元。公司的營收同比下降 1.5%。分析師維持 “適度買入” 評級，目標價共識為 72.77 美元。機構投資者持有 98.95% 的股份。Bio-Techne 專注於生命科學產品，包括用於研究和診斷的試劑和儀器</p>

<p>Bio-Techne Corp (NASDAQ:TECH - Get Free Report)'s stock price dropped 10.8% on Wednesday following a weaker than expected earnings announcement. The company traded as low as $49.77 and last traded at $50.5320. Approximately 2,041,218 shares traded hands during trading, a decline of 12% from the average daily volume of 2,317,194 shares. The stock had previously closed at $56.68.</p>
<div class="lb-trans"><p>Bio-Techne Corp (NASDAQ:TECH - 獲取免費報告) 的股價在週三下跌了 10.8%，原因是其財報表現低於預期。該公司股價最低曾達到 49.77 美元，最後交易價為 50.5320 美元。在交易過程中，約有 2,041,218 股成交，較日均成交量 2,317,194 股下降了 12%。該股票此前收盤價為 56.68 美元。</p>
</div><ul>
<li>Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points</li>
</ul>
<div class="lb-trans"><ul>
<li>Bio-Techne、J2 Global 和 InMode 從底部突破，接近買入點</li>
</ul>
</div><p>The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.02). The business had revenue of $311.42 million for the quarter, compared to analyst estimates of $316.08 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The firm's revenue was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share.</p>
<div class="lb-trans"><p>這家生物技術公司報告本季度每股收益為 0.53 美元，低於市場共識預期的 0.55 美元，差距為 0.02 美元。該公司本季度的收入為 3.1142 億美元，而分析師預期為 3.1608 億美元。Bio-Techne 的淨利潤率為 6.67%，股本回報率為 13.94%。該公司的收入同比下降了 1.5%。在去年同期，該公司每股收益為 0.56 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>TECH has been the topic of several research analyst reports. Benchmark reiterated a &#34;buy&#34; rating on shares of Bio-Techne in a research report on Tuesday, February 3rd. Wells Fargo &amp; Company lifted their price objective on shares of Bio-Techne from $70.00 to $76.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, February 6th. Zacks Research upgraded shares of Bio-Techne from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, February 9th. Evercore boosted their price target on shares of Bio-Techne from $62.00 to $68.00 and gave the company an &#34;in-line&#34; rating in a report on Thursday, February 5th. Finally, TD Cowen restated a &#34;buy&#34; rating on shares of Bio-Techne in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Bio-Techne currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $72.77.</p>
<div class="lb-trans"><p>TECH 已成為多份研究分析報告的主題。Benchmark 在 2 月 3 日的研究報告中重申了對 Bio-Techne 股票的 “買入” 評級。富國銀行在 2 月 6 日的研究報告中將 Bio-Techne 的目標價從 70.00 美元上調至 76.00 美元，並給予該股票 “超配” 評級。Zacks Research 在 2 月 9 日的報告中將 Bio-Techne 的評級從 “強烈賣出” 上調至 “持有”。Evercore 在 2 月 5 日的報告中將 Bio-Techne 的目標價從 62.00 美元上調至 68.00 美元，並給予該公司 “持平” 評級。最後，TD Cowen 在 3 月 17 日的報告中重申了對 Bio-Techne 股票的 “買入” 評級。一位投資分析師給予該股票 “強烈買入” 評級，九位給予 “買入” 評級，三位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Bio-Techne 目前的平均評級為 “適度買入”，共識目標價為 72.77 美元。</p>
</div><p><strong>Read Our Latest Analysis on Bio-Techne</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Bio-Techne 的最新分析</strong></p>
</div><h2>Institutional Trading of Bio-Techne</h2>
<div class="lb-trans"><h2>Bio-Techne 的機構交易</h2>
</div><p>Several hedge funds have recently modified their holdings of the stock. Asset Management One Co. Ltd. boosted its stake in Bio-Techne by 2.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 5,752 shares of the biotechnology company's stock valued at $341,000 after acquiring an additional 153 shares during the last quarter. Accredited Investors Inc. raised its holdings in shares of Bio-Techne by 2.7% during the fourth quarter. Accredited Investors Inc. now owns 6,052 shares of the biotechnology company's stock worth $356,000 after acquiring an additional 161 shares during the period. Allworth Financial LP increased its stake in Bio-Techne by 28.4% in the 3rd quarter. Allworth Financial LP now owns 786 shares of the biotechnology company's stock valued at $44,000 after buying an additional 174 shares during the last quarter. Oppenheimer &amp; Co. Inc. grew its position in shares of Bio-Techne by 3.5% in the 4th quarter. Oppenheimer &amp; Co. Inc. now owns 5,351 shares of the biotechnology company's stock valued at $315,000 after acquiring an additional 181 shares during the period. Finally, Angeles Wealth Management LLC lifted its holdings in Bio-Techne by 3.4% during the 3rd quarter. Angeles Wealth Management LLC now owns 5,703 shares of the biotechnology company's stock valued at $317,000 after purchasing an additional 189 shares during the last quarter. 98.95% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金最近調整了對該股票的持有。Asset Management One Co. Ltd.在第四季度將其在 Bio-Techne 的持股增加了 2.7%。Asset Management One Co. Ltd.目前擁有 5,752 股該生物技術公司的股票，價值 341,000 美元，此前在上個季度增持了 153 股。Accredited Investors Inc.在第四季度將其在 Bio-Techne 的持股增加了 2.7%。Accredited Investors Inc.目前擁有 6,052 股該生物技術公司的股票，價值 356,000 美元，此前增持了 161 股。Allworth Financial LP 在第三季度將其在 Bio-Techne 的持股增加了 28.4%。Allworth Financial LP 目前擁有 786 股該生物技術公司的股票，價值 44,000 美元，此前增持了 174 股。Oppenheimer &amp; Co. Inc.在第四季度將其在 Bio-Techne 的持股增加了 3.5%。Oppenheimer &amp; Co. Inc.目前擁有 5,351 股該生物技術公司的股票，價值 315,000 美元，此前增持了 181 股。最後，Angeles Wealth Management LLC 在第三季度將其在 Bio-Techne 的持股增加了 3.4%。Angeles Wealth Management LLC 目前擁有 5,703 股該生物技術公司的股票，價值 317,000 美元，此前增持了 189 股。98.95% 的股票由機構投資者持有。</p>
</div><h2>Bio-Techne Stock Down 10.6%</h2>
<div class="lb-trans"><h2>Bio-Techne 股價下跌 10.6%</h2>
</div><p>The firm has a market cap of $7.92 billion, a P/E ratio of 99.38, a P/E/G ratio of 3.60 and a beta of 1.41. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.08 and a current ratio of 4.54. The firm's fifty day moving average is $54.70 and its 200 day moving average is $59.71.</p>
<div class="lb-trans"><p>該公司的市值為 79.2 億美元，市盈率為 99.38，市盈增長比率為 3.60，貝塔值為 1.41。該公司的債務與股本比率為 0.13，速動比率為 3.08，流動比率為 4.54。該公司的 50 日移動平均線為 54.70 美元，200 日移動平均線為 59.71 美元。</p>
</div><h2>Bio-Techne Company Profile</h2>
<div class="lb-trans"><h2>Bio-Techne 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&amp;D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.</p>
<div class="lb-trans"><p>Bio-Techne Corporation NASDAQ: TECH 是一家全球生命科學公司，開發、製造和銷售高質量的試劑、儀器和服務，服務於研究、診斷和生物加工市場。其核心產品包括重組蛋白、抗體、免疫測定、核酸探針和試劑盒、單細胞分析解決方案以及自動化蛋白分析系統。旗艦品牌如 R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 為研究人員和臨牀醫生提供可靠的細胞生物學、免疫學、蛋白質組學和基因組學應用工具。</p>
</div><p>Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.</p>
<div class="lb-trans"><p>Bio-Techne 總部位於明尼阿波利斯，明尼蘇達州，通過直接銷售、分銷商和戰略合作伙伴關係為北美、歐洲和亞太地區的客户提供服務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Bio-Techne</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Bio-Techne</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Techne Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Bio-Techne 嗎？</h2>
</div><p>Before you consider Bio-Techne, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Bio-Techne 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Bio-Techne 並不在名單上。</p>
</div><p>While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bio-Techne 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bio-Techne (NASDAQ:TECH) 股價因業績不佳下跌 10.8%